TTK Healthcare (TTKHLTCARE)
Slow GrowerFairStock Score: 31/100 — RISKY
Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,157.7 |
| Market Cap | ₹1,635.87 Cr |
| P/E Ratio | 22.12 |
| ROCE | 9.26% |
| ROE | 5.78% |
| Dividend Yield | 0.86% |
| Profit Growth | 63.69% |
| Debt/Equity | 0.02 |
| Sales Growth | 12.27% |
| Promoter Holding | 74.56% |
| 52-Week Range | ₹735 — ₹1,250 |
| Sector | Diversified |
| Book Value | ₹788.98 |
Strengths
- Very low leverage with Debt/Equity of 0.02, providing financial safety
- High promoter holding of 74.56%, aligning management with shareholders
- Price-to-book of 1.30 is moderate against book value of ₹717.42
- Pays a dividend yield of 1.10%, indicating some return to shareholders
Concerns
- ROE of 5.78% and ROCE of 9.26% are weak returns on capital
- Sales growth of only 2.23% and profit decline of -5.92% show stagnation
- P/E of 18.43 and PEG of 8.26 look expensive relative to near-zero growth
- Piotroski F-score of 4/9 and FairStock Score of 17/100 signal fundamental risk
AI Analysis
When I look at TTK Healthcare, I start with returns on capital. A 5.78% ROE and 9.26% ROCE tell me this is not a wonderful compounding machine. Sales grew only 2.23% and profits actually fell 5.92%. The latest quarter shows ₹209 Cr sales and ₹11 Cr net profit — no strong momentum. At ₹930.60, the P/E is 18.43, and with negative profit growth, the PEG of 8.26 makes no sense. Paying a growth multiple for a business that isn't growing is not my idea of value investing. Book value is ₹717.42, so the P/B is 1.30 — not cheap enough to provide a real margin of safety. To be fair, the balance sheet is clean: debt-to-equity of 0.02, and promoter holding of 74.56% means owners are aligned with minority shareholders. The dividend yield of 1.10% is modest but not compelling. However, the Piotroski F-score of 4 out of 9 is weak, and the FairStock score of 17/100 flags risk. In Graham's language, this is not a bargain; it's a mediocre business with a clean balance sheet and no earnings growth. A low-debt company can survive, but survival is not the same as creating wealth. I need a margin of safety in either price or business quality. TTK Healthcare offers neither convincingly today. I would pass and keep my capital for a better opportunity.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer